A Study to Assess Disease Activity of Intravenously (IV) Infused Telisotuzumab Vedotin in Adult Participants with Advanced/Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

You likely can't join if

• Subject must not have clinically significant condition(s) including but not limited to the following: 1) Clinically significant vascular disease, including: Myocardial infarction within 1 year or stroke within 6 months prior to first dose of study drug, or unstable or uncontrolled disease/condition related to or affecting cardiac function (e.g., unstable angina, congestive heart failure, New York Heart Association Class III – IV), cardiac arrhythmia (CTCAE Version 5 Grade 2 or higher), or clinically significant electrocardiogram (ECG) abnormalities. 2) Clinically significant liver disease, including hepatitis, current alcohol abuse, or cirrhosis. 3) Grade ≥ 2 edema or lymphedema. 4) Grade ≥ 2 ascites or pleural effusion. 5) Grade ≥ 2 neuropathy. 6) Active uncontrolled bacterial or viral infection.
• Subjects with alterations in EGFR, ALK, ROS1, or BRAF that predict sensitivity to available targeted therapy are not eligible. Subjects with other alterations that are candidates for available targeted therapy are not eligible.
• Subject must have no prior systemic therapy for locally advanced/metastatic NSCLC. Limited treatment with no more than 1 cycle of chemotherapy is allowed prior to receiving the first dose of study drug provided there is no evidence of progression. Subject may have received prior adjuvant/neoadjuvant systemic chemotherapy and/or radiation and/or immunotherapy provided that the subject has not progressed on or within 6 months of completing the regimen and it was completed ≥ 6 months before subject's first dose of study drug.
• Subject must not have received prior c-Met-targeted antibodies.
• Subject must not have NSCLC that is eligible for treatment with curative intent.
• Subjects must not have a history of other malignancies except: 1) Malignancy treated with curative intent and with no known active disease present for ≥ 2 years before the first dose of study drug and felt to be at low risk for recurrence by investigator. 2) Adequately treated non-melanoma skin cancer or lentigo maligna without evidence of disease. 3) Adequately treated carcinoma in situ without current evidence of disease.